TREVI THERAPEUTIC DL-,001

Trevi Therapeutics presented Haduvio at a specialist conference as a centrally acting treatment for cough in IPF, ILD and refractory chronic cough, emphasizing that the mechanism targets the brain. Two Phase III studies for IPF (OCEAN-1, OCEAN-2) are ongoing; the RCC study LAKE is evaluating a sample-size adjustment through the end of 2024; and an FDA meeting on the ILD program is planned for Q4 2024. The company reports $319 million in cash, sees no near-term need for financing, and is targeting key Phase III readouts in the second half of 2027. Management cites the failure of peripheral approaches as validation of the central mechanism but warns of the usual development and reimbursement risks. » More on de.investing.com

Clear Street raises its price target for Trevi Therapeutics to $40 after GSK halted development of Camlipixant for refractory chronic cough. The removal of the competing drug increases the market potential for Trevi’s Haduvio, and analysts raise the assumed annual price of the therapy to $100,000. A recently completed financing strengthens the balance sheet and secures liquidity through 2030. » More on finanzen.net

Trevi Therapeutics' stock hit a new all‑time high of $19.33 and is currently trading at $19.48; year‑to‑date the share price has risen 226.05% and market capitalization is about $2.69 billion. InvestingPro views the stock as overvalued relative to its fair‑value estimate, while one analyst highlights the high annual return. Trevi reported strong cash reserves of about $334 million after an April offering, intended to fund operations through 2030, and is preparing a regulatory two‑study program for Haduvio in IPF‑CC following an end‑of‑phase‑2 meeting with the FDA; initial data are expected in 2027. Stifel confirmed the rating. » More on de.investing.com